Salud financiera de hoja de balance de Oncternal Therapeutics
Salud financiera controles de criterios 6/6
Oncternal Therapeutics tiene un patrimonio de los accionistas total de $30.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $36.7M y $6.7M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$34.26m |
| Patrimonio | US$30.05m |
| Total pasivo | US$6.68m |
| Activos totales | US$36.73m |
Actualizaciones recientes sobre salud financiera
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12Recent updates
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01Oncternal: Solid Data In Tough-To-Treat Cancer
Jan 31Oncternal Therapeutics: Recent Success Points To A Bright Future
Jan 29Oncternal inks manufacturing deal with Miltenyi Biotec subsidiary
Jan 14Oncternal and karolinska Institutet ink research deal for ROR1-targeting cell therapies
Jan 07Oncternal Therapeutics soars after presenting data at ASH
Dec 07Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($36.1M) de ONCT superan a sus pasivos a corto plazo ($5.2M).
Pasivo a largo plazo: Los activos a corto plazo de ONCT ($36.1M) superan a sus pasivos a largo plazo ($1.5M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ONCT está libre de deudas.
Reducción de la deuda: ONCT no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ONCT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ONCT dispone de suficiente cash runway para 1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 25.6% cada año.